HIFU is a potentially effective treatment of localized prostate cancer with a low Prostate Cancer-specific mortality rate of 10 years as well as acceptable morbidity. This treatment is listed in the PC treatment option formed by European Urology in 2014.
This specialized treatment can emit precise and high-intensity energy in a designated area to provide effective treatment without harming surrounding normal cells.
It is suitable for men who are not suitable for surgery due to their age or other associated illnesses, or who may not want to undergo traditional surgery. It may also be suitable for men with cancer having recurrence followed by radiotherapy.
HIFU is a type of targeted treatment for localized prostate cancer that does not require surgery; therefore, there is no wound. Patients can be discharged from the hospital within 3 days.
HIFU patients are highly contented with this treatment due to less complications and better results. Also, most patients can achieve three major purposes after the operation: cancer control, no incontinence, and no sexual dysfunction.